Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials

Thomas Yates; Jack A. Sargeant; James A. King; Joe Henson; Charlotte L. Edwardson; Emma Redman; Gaurav S. Gulsin; Emer M. Brady; Ehtasham Ahmad; David J. Stensel; David R. Webb; Gerry P. McCann; Kamlesh Khunti; Melanie J. Davies

doi:10.2337/dc22-0888

Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials

Thomas Yates^*, Jack A. Sargeant, James A. King, Joe Henson, Charlotte L. Edwardson, Emma Redman, Gaurav S. Gulsin, Emer M. Brady, Ehtasham Ahmad, David J. Stensel, David R. Webb, Gerry P. McCann, Kamlesh Khunti, Melanie J. Davies

^*Corresponding author for this work

Graduate School of Sport Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity. RESULTS Liraglutide (mean 21,144 steps/day; 95% CI 22,069 to 2220), empagliflozin (21,132 steps/day; 21,739, 2524), and sitagliptin (2852 steps/day; 21,625, 278) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate-to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.

Original language	English
Pages (from-to)	2749-2752
Number of pages	4
Journal	Diabetes care
Volume	45
Issue number	11
DOIs	https://doi.org/10.2337/dc22-0888
Publication status	Published - 2022 Nov

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialised Nursing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2337/dc22-0888

Cite this

Yates, T., Sargeant, J. A., King, J. A., Henson, J., Edwardson, C. L., Redman, E., Gulsin, G. S., Brady, E. M., Ahmad, E., Stensel, D. J., Webb, D. R., McCann, G. P., Khunti, K., & Davies, M. J. (2022). Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Diabetes care, 45(11), 2749-2752. https://doi.org/10.2337/dc22-0888

Yates, T, Sargeant, JA, King, JA, Henson, J, Edwardson, CL, Redman, E, Gulsin, GS, Brady, EM, Ahmad, E, Stensel, DJ, Webb, DR, McCann, GP, Khunti, K & Davies, MJ 2022, 'Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials', Diabetes care, vol. 45, no. 11, pp. 2749-2752. https://doi.org/10.2337/dc22-0888

@article{bc2eadc57c9743edac5b5b934729464d,

title = "Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials",

abstract = "OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity. RESULTS Liraglutide (mean 21,144 steps/day; 95% CI 22,069 to 2220), empagliflozin (21,132 steps/day; 21,739, 2524), and sitagliptin (2852 steps/day; 21,625, 278) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate-to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.",

author = "Thomas Yates and Sargeant, {Jack A.} and King, {James A.} and Joe Henson and Edwardson, {Charlotte L.} and Emma Redman and Gulsin, {Gaurav S.} and Brady, {Emer M.} and Ehtasham Ahmad and Stensel, {David J.} and Webb, {David R.} and McCann, {Gerry P.} and Kamlesh Khunti and Davies, {Melanie J.}",

note = "Funding Information: was funded by a grant from NIHR (CDF 2014-07-045). Funding Information: Funding. This study was in part supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. DIASTOLIC Publisher Copyright: {\textcopyright} 2022 by the American Diabetes Association.",

year = "2022",

month = nov,

doi = "10.2337/dc22-0888",

language = "English",

volume = "45",

pages = "2749--2752",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "11",

}

TY - JOUR

T1 - Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels

T2 - Pooled Analysis From Three Randomized Trials

AU - Yates, Thomas

AU - Sargeant, Jack A.

AU - King, James A.

AU - Henson, Joe

AU - Edwardson, Charlotte L.

AU - Redman, Emma

AU - Gulsin, Gaurav S.

AU - Brady, Emer M.

AU - Ahmad, Ehtasham

AU - Stensel, David J.

AU - Webb, David R.

AU - McCann, Gerry P.

AU - Khunti, Kamlesh

AU - Davies, Melanie J.

N1 - Funding Information: was funded by a grant from NIHR (CDF 2014-07-045). Funding Information: Funding. This study was in part supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. DIASTOLIC Publisher Copyright: © 2022 by the American Diabetes Association.

PY - 2022/11

Y1 - 2022/11

N2 - OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity. RESULTS Liraglutide (mean 21,144 steps/day; 95% CI 22,069 to 2220), empagliflozin (21,132 steps/day; 21,739, 2524), and sitagliptin (2852 steps/day; 21,625, 278) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate-to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.

AB - OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity. RESULTS Liraglutide (mean 21,144 steps/day; 95% CI 22,069 to 2220), empagliflozin (21,132 steps/day; 21,739, 2524), and sitagliptin (2852 steps/day; 21,625, 278) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate-to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity. CONCLUSIONS The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.

UR - http://www.scopus.com/inward/record.url?scp=85141367988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141367988&partnerID=8YFLogxK

U2 - 10.2337/dc22-0888

DO - 10.2337/dc22-0888

M3 - Article

C2 - 35984425

AN - SCOPUS:85141367988

SN - 0149-5992

VL - 45

SP - 2749

EP - 2752

JO - Diabetes care

JF - Diabetes care

IS - 11

ER -

Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this